Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089569 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine
A NA study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT01089569 is a NA study that has completed, run by HealthPartners Institute. The registered enrollment target is 60 participants.
The verdict
NCT01089569, a NA study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the effect on 24-hour blood glucose patterns, HbA1c, and weight management when adding insulin glargine, or exenatide, or a combination of insulin glargine and exenatide to metformin.
Interventions
- DRUG Exenatide
- DRUG Insulin Glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01089569
The ClinicalTrials.gov registry entry for NCT01089569 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exenatide is the first listed.
NCT01089569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01089569 about?
NCT01089569 is a clinical study titled "Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine". The primary purpose of this study is to compare the effect on 24-hour blood glucose patterns, HbA1c, and weight management when adding insulin glargine, or exenatide, or a combination of insulin glargine and exenatide to metformin.
What is the current status of trial NCT01089569?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2010-04. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01089569?
The interventions under investigation include: Exenatide (DRUG), Insulin Glargine (DRUG).
Who is sponsoring clinical trial NCT01089569?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.